-+ 0.00%
-+ 0.00%
-+ 0.00%

Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL

Benzinga·11/17/2026 08:12:02

– TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG ≥880 mg/dL (≥10 mmol/L) –

– Approximately 700,000 people in the EU5 are estimated to have triglyceride levels ≥880 mg/dL (≥10 mmol/L) and at high risk of developing acute pancreatitis –